Drug Trial Radar · NCT06323356
A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Mar 19, 2024
Primary completion
Oct 17, 2025
Study completion Jul 10, 2026
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Mar 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study treatment or TAK-279. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 61 weeks including 52 weeks of study treatment. During the study, participants will visit their study clinic for multiple times.
Conditions
- Generalized Pustular Psoriasis
- Erythrodermic Psoriasis
Interventions
TAK-279Drug
Specified drug on specified days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a Greater Than or Equal to (>=) 2-Point Decrease From Baseline at Week 16Time frame: At Week 16
- Percentage of Participants Who Achieved >=75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 16Time frame: At Week 16
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Fukuoka University Hospital
Fukuoka, Japan
University Hospital, Kyoto Prefectural University of Medicine
Kyoto, Japan
Okayama University Hospital
Okayama, Japan
Nippon Life Hospital
Osaka, Japan
Osaka Metropolitan University Hospital
Osaka, Japan
Nagoya City University Hospital
Nagoya, Aichi-ken, Japan
Fujita Health University Hospital
Toyoake, Aichi-ken, Japan
Kimitsu Chuo Hospital
Kisarazu, Chiba, Japan
Juntendo University Urayasu Hospital
Urayasu, Chiba, Japan
Hospital of the University of Occupational and Environmental Health, Japan
Kitakyushu, Fukuoka, Japan
Isesaki Municipal Hospital
Isesaki, Gunma, Japan
Kobe University Hospital
Kobe, Hyōgo, Japan
Tokai University Hospital
Isehara, Kanagawa, Japan
Mie University Hospital
Tsu, Mie-ken, Japan
Kansai Medical University Hospital
Hirakata, Osaka, Japan
Saitama Medical University Hospital
Iruma, Saitama, Japan
St.Luke's International Hospital
Chūō, Tokyo, Japan
The Jikei University Hospital
Minato-ku, Tokyo, Japan
Tokyo Medical University Hospital
Shinjuku-ku, Tokyo, Japan
Teikyo University Hospital
tabashi City, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.